• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TNYA

    Tenaya Therapeutics Inc.

    Subscribe to $TNYA
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: tenayatherapeutics.com

    Peers

    $AXSM
    $BTAI
    $GTHX
    $RLAY
    $SGTX
    $TPST
    $ELYM

    Recent Analyst Ratings for Tenaya Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    See more ratings

    Tenaya Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Stehman-Breen Catherine

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:54:13 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walsh Jeffrey T.

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:53:37 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Burroughs Amy L.

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:52:57 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Goeddel David V

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:52:21 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Williams R Sanders

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:51:21 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Srivastava Deepak

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:50:50 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Lee June

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:50:27 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Parschauer Karah Herdman

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/30/25 6:48:35 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Finance Higa Tomohiro sold $615 worth of shares (1,390 units at $0.44), decreasing direct ownership by 1% to 98,300 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/16/25 7:07:53 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Tingley Whittemore sold $1,300 worth of shares (2,937 units at $0.44), decreasing direct ownership by 2% to 171,856 units (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      5/16/25 7:07:25 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:40 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      3/7/25 7:14:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:15:53 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goeddel David V bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

      4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

      2/14/24 4:12:27 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. SEC Filings

    See more
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/30/25 4:32:02 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/15/25 9:32:51 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Tenaya Therapeutics Inc.

      SCHEDULE 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/14/25 4:18:42 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tenaya Therapeutics Inc.

      10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:27:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      5/7/25 4:18:33 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tenaya Therapeutics Inc.

      SCHEDULE 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)

      5/7/25 9:31:20 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tenaya Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/18/25 5:07:15 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Tenaya Therapeutics Inc.

      DEFA14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/17/25 4:08:26 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Tenaya Therapeutics Inc.

      DEF 14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/17/25 4:05:42 PM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Tenaya Therapeutics Inc.

      EFFECT - Tenaya Therapeutics, Inc. (0001858848) (Filer)

      4/1/25 12:15:21 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Tenaya Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Tenaya Therapeutics

      William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

      6/10/24 7:25:34 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

      Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

      11/30/23 7:50:26 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

      6/15/22 7:41:04 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cowen & Co. initiated coverage on Tenaya Therapeutics

      Cowen & Co. initiated coverage of Tenaya Therapeutics with a rating of Outperform

      8/24/21 7:24:12 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on Tenaya Therapeutics with a new price target

      Morgan Stanley initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $31.00

      8/24/21 7:23:09 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital initiated coverage on Tenaya Therapeutics with a new price target

      Chardan Capital initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $37.00

      8/24/21 6:03:25 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Tenaya Therapeutics with a new price target

      Piper Sandler initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $40.00

      8/24/21 5:15:10 AM ET
      $TNYA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care